Doctor warns of rise in problems from Turkish weight loss surgery

An obesity doctor has told an inquest his team has dealt with more than 100 problems in patients who have undergone weight loss surgery in Turkey.Tanveer Adil, who works at Luton & Dunstable Hospital, was giving evidence at the inquest of 40-year-old Hayley Butler, a dog groomer from Norwich who died of organ failure after a sleeve gastrectomy at the Ozel Gozde Hospital in Izmir.He said Miss Butler had died as a result of the procedure and the "lack of safety netting" afterwards.Norfolk area coroner Yvonne Blake said it was clear the operation "had not been done properly".
Miss Butler flew to Izmir with a friend in September 2024 for the operation to remove a large part of her stomach after apparently failing to get help in the UK, the inquest in Norwich heard.Flights, transfers, accommodation, pre-op tests and medication were all included in the trip at a cost of about £2,500.After the procedure, the hearing was told she was given a 'fit to fly' letter from the hospital and returned home two days later, but was already feeling unwell. In a statement read by the coroner, her mother Gill Moore said Miss Butler was "constantly thirsty and had no energy... but thought it was normal". She added: "Things got worse over the weekend of the 5 October; she was projectile vomiting and could only consume tiny amounts of anything."Miss Butler was admitted to Norfolk and Norwich Hospital and later transferred to a specialist bariatric unit at Luton and Dunstable Hospital on the morning of 11 October. She eventually went into surgery at 17:00 and afterwards Mrs Moore said she was told her daughter had a 30% chance of survival.She died on 24 October of multiple organ failure due to sepsis.Mrs Moore said a doctor told her it was "the worst case he'd ever seen".
Mr Adil told the court surgeons found fluid in Miss Butler's abdomen and four perforations in organs. He said it was his opinion the cause of her death was "what happened in Turkey and the lack of safety netting after major bariatric surgery". The tertiary bariatric unit at his hospital had witnessed a "significant rise in complications" from similar procedures in the country, he told the hearing."We have managed more than 100 such complications in our unit, which is a matter of significant concern," said Mr Adil.Mrs Moore said there was a lack of communication and support from medics at the Luton hospital as her daughter's life support was removed and she died, which she said would haunt her for the rest of her life.Coroner Ms Blake, who recorded a narrative conclusion, said that "the way they [staff] left you to be with Hayley when she died was astonishing".She said she would raise concerns about Miss Butler's sleeve gastrectomy with regulators in Turkey.The Ozel Gozde Hospital and Luton & Dunstable Hospital have been approached for comment.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

The Independent

3 hours ago

• The Independent

Weight loss pill shows promise in new trial

A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.

Reuters

5 hours ago

• Reuters

Novo Nordisk's experimental drug results in up to 24% weight loss

June 20 (Reuters) - Novo Nordisk ( opens new tab on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24% of their weight as the Danish company readies for late-stage studies, opens new tab to start next year. The company said side effects of the drug, tested as both a weekly injection and a daily pill, were mostly gastrointestinal with rates similar to other recent weight loss drugs. The full trial results were presented at the annual meeting of the American Diabetes Association in Chicago and published in the Lancet medical journal. Novo's head of development Martin Holst Lange said the Phase 3 amycretin program starting in 2026 will run "for a couple of years" after which the regulatory review process could start. The company earlier this month said it planned to start late-stage trials of the drug in the first quarter of 2026 after previously announcing the early-stage trial results. Amycretin has a dual-mode action. Like Novo's popular weight-loss drug Wegovy, it mimics the gut hormone GLP-1, but also targets receptors for a hunger-suppressing pancreatic hormone called amylin. Trial results showed that 20-milligram weekly injections of the drug helped overweight or obese patients without diabetes lose 22% of their weight over 36 weeks, with a 60-mg dose resulting in 24.3% weight loss. In the Phase 1 study of once-daily oral amycretin, patients received increasing doses, ranging from 3 mg to a final dose of 100 mg. Patients who took 50 mg of amycretin at the end of the 12-week trial reduced body weight by 10.4% on average, while those taking the maximum dose lost 13.1% of their weight, the company said. Novo said the weight loss did not plateau, suggesting that longer treatment could lead to greater weight loss. In a Lancet commentary, researchers not involved in the amycretin studies said that "while additional weight loss is welcome and helpful, our evolving concept of obesity management has now shifted towards an emphasis on the reduction of the risks and burdens of cardiovascular disease and other comorbidities." Commentators Tricia Tan, professor of metabolic medicine and endocrinology at Imperial College London, and endocrinologist Dr. Bernard Khoo, said studies directly comparing GLP-1 drugs like Novo's Ozempic to drugs like amycretin will be needed to definitively establish their added value and place in obesity management.

Daily Mail​

5 hours ago

• Daily Mail​

Ozempic-maker's new fat-busting drug cuts body weight by a quarter - and it comes as a jab or a PILL

A new fat-busting drug that is available as a jab or tablet helps patients lose up to a quarter of their body weight, studies suggest. People who received higher doses of amycretin as a weekly injection lost 24.3 per cent of their body weight after 36 weeks of treatment. And those taking daily tablets lost an average of 13.1 per cent of their body weight after 12 weeks, the early stage trials found. Weight loss jabs have been hailed as transformative by NHS leaders. But tablets could be the next big breakthrough in the nation's fight against obesity as they are likely to appeal to a wider audience who are uncomfortable with injecting themselves. An estimated 1.5million Britons use weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out fat jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body—GLP-1 and the amylin receptor. In comparison to amycretin, trials pivotal to getting semaglutide—the ingredient behind Ozempic—approved, show it helped users shed up to 15 per cent of their body weight over 68 weeks. And studies have found rival jab Mounjaro can help obese people lose up to 22.5 per cent of their body weight in 72 weeks. The new amycretin trial involved 125 adults, who took weekly injections of the drug. Those taking the highest dosage (60mg) lost 24.3 per cent after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment, according to findings published in medical journal The Lancet. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1 per cent of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7 per cent, with a third of participants losing 25 per cent or more of their body weight after 72 weeks. GLP-1 injections suffered global shortages after celebrity users sparked a surge in popularity and the NHS has warned people against buying them from unauthorised sources. Professor Sir Stephen Powis, national medical director at NHS England, last week told the NHS ConfedExpo conference in Manchester that weight loss jabs could be doled out as widely as statins if competition in the market brings their price down The country's top doctor warned obesity costs the NHS £11.4billion every year and described the financial burden as 'unsustainable'. From Monday, GPs will be able to prescribe the fat jab mounjaro - also known as tirzepatide - for the first time, in what he labelled an 'exciting milestone'.